KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EBITDA (2018 - 2025)

Historic EBITDA for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $10.3 million.

  • Adaptive Biotechnologies' EBITDA rose 17195.8% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$59.2 million, marking a year-over-year increase of 5509.21%. This contributed to the annual value of -$162.5 million for FY2024, which is 2840.36% up from last year.
  • As of Q3 2025, Adaptive Biotechnologies' EBITDA stood at $10.3 million, which was up 17195.8% from -$6.1 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' EBITDA ranged from a high of $10.3 million in Q3 2025 and a low of -$71.1 million during Q4 2023
  • Its 5-year average for EBITDA is -$36.4 million, with a median of -$37.1 million in 2023.
  • In the last 5 years, Adaptive Biotechnologies' EBITDA crashed by 8136.07% in 2023 and then surged by 17195.8% in 2025.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' EBITDA stood at -$61.6 million in 2021, then surged by 36.38% to -$39.2 million in 2022, then plummeted by 81.36% to -$71.1 million in 2023, then surged by 52.39% to -$33.8 million in 2024, then skyrocketed by 130.41% to $10.3 million in 2025.
  • Its EBITDA stands at $10.3 million for Q3 2025, versus -$6.1 million for Q2 2025 and -$29.6 million for Q1 2025.